Corbus Pharmaceuticals (CRBP) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Corbus Pharmaceuticals (NASDAQ: CRBP) recently:

• 8/13/2026 – Corbus Pharmaceuticals was given a new $33.00 price target by Mizuho.
• 8/8/2026 – Corbus Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/7/2026 – Corbus Pharmaceuticals had its price target lowered by Oppenheimer Holdings, Inc. from $52.00 to $48.00. They now have an “outperform” rating on the stock.
• 8/7/2026 – Corbus Pharmaceuticals had its price target lowered by HC Wainwright from $40.00 to $35.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Corbus Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/23/2026 – Corbus Pharmaceuticals had its price target lowered by Mizuho from $44.00 to $34.00. They now have an “outperform” rating on the stock.
• 6/20/2026 – Corbus Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 6/17/2026 – Corbus Pharmaceuticals had its price target lowered by Oppenheimer Holdings, Inc. from $54.00 to $52.00. They now have an “outperform” rating on the stock.

Insider Transactions at Corbus Pharmaceuticals

In related news, CFO Sean F. Moran sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $120,960.00. Following the completion of the transaction, the chief financial officer directly owned 84,694 shares of the company’s stock, valued at $853,715.52. This trade represents a 12.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yuval Cohen sold 17,000 shares of Corbus Pharmaceuticals stock in a transaction on Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $171,360.00. Following the transaction, the chief executive officer directly owned 157,316 shares of the company’s stock, valued at approximately $1,585,745.28. This represents a 9.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders acquired 16,100 shares of company stock worth $126,243 and sold 38,238 shares worth $365,393. 3.50% of the stock is currently owned by corporate insiders.

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.